These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38496221)

  • 1. Orexin Receptor Antagonists as Adjunct Drugs for the Treatment of Depression: A Mini Meta-Analysis.
    Uğurlu M
    Noro Psikiyatr Ars; 2024; 61(1):77-84. PubMed ID: 38496221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orexin Receptor Antagonists and Insomnia.
    Wu X; Xue T; Chen Z; Wang Z; Chen G
    Curr Psychiatry Rep; 2022 Oct; 24(10):509-521. PubMed ID: 35972717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orexin Receptor Antagonists in the Treatment of Depression: A Leading Article Summarising Pre-clinical and Clinical Studies.
    Fagan H; Jones E; Baldwin DS
    CNS Drugs; 2023 Jan; 37(1):1-12. PubMed ID: 36436175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders.
    Muehlan C; Vaillant C; Zenklusen I; Kraehenbuehl S; Dingemanse J
    Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1063-1078. PubMed ID: 32901578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orexin/hypocretin receptor modulation of anxiolytic and antidepressive responses during social stress and decision-making: Potential for therapy.
    Summers CH; Yaeger JDW; Staton CD; Arendt DH; Summers TR
    Brain Res; 2020 Mar; 1731():146085. PubMed ID: 30590027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia.
    Brooks S; Jacobs GE; de Boer P; Kent JM; Van Nueten L; van Amerongen G; Zuiker R; Kezic I; Luthringer R; van der Ark P; van Gerven JM; Drevets W
    J Psychopharmacol; 2019 Feb; 33(2):202-209. PubMed ID: 30644312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.
    De Crescenzo F; D'Alò GL; Ostinelli EG; Ciabattini M; Di Franco V; Watanabe N; Kurtulmus A; Tomlinson A; Mitrova Z; Foti F; Del Giovane C; Quested DJ; Cowen PJ; Barbui C; Amato L; Efthimiou O; Cipriani A
    Lancet; 2022 Jul; 400(10347):170-184. PubMed ID: 35843245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orexin Receptor Antagonism: Normalizing Sleep Architecture in Old Age and Disease.
    Kron JOJ; Keenan RJ; Hoyer D; Jacobson LH
    Annu Rev Pharmacol Toxicol; 2024 Jan; 64():359-386. PubMed ID: 37708433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant.
    Khazaie H; Sadeghi M; Khazaie S; Hirshkowitz M; Sharafkhaneh A
    Front Psychiatry; 2022; 13():1070522. PubMed ID: 36578296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis.
    Xue T; Wu X; Li J; Chen S; Wang Z; Tan X; Wang Z; Zhang J
    Front Pharmacol; 2023; 14():1175372. PubMed ID: 37261282
    [No Abstract]   [Full Text] [Related]  

  • 12. Evidence-based insomnia treatment strategy using novel orexin antagonists: A review.
    Kishi T; Nishida M; Koebis M; Taninaga T; Muramoto K; Kubota N; Moline M; Sakuma K; Okuya M; Nomura I; Iwata N
    Neuropsychopharmacol Rep; 2021 Dec; 41(4):450-458. PubMed ID: 34553844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lemborexant, an orexin receptor antagonist sedative-hypnotic: Is it useful for insomnia in psychiatric disorders?
    Keks NA; Hope J
    Australas Psychiatry; 2022 Aug; 30(4):530-532. PubMed ID: 35491942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics.
    Janto K; Prichard JR; Pusalavidyasagar S
    J Clin Sleep Med; 2018 Aug; 14(8):1399-1408. PubMed ID: 30092886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
    Hoyer D; Jacobson LH
    Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of pharmacological treatments for insomnia in adults: A systematic review and network meta-analysis.
    Yue JL; Chang XW; Zheng JW; Shi L; Xiang YJ; Que JY; Yuan K; Deng JH; Teng T; Li YY; Sun W; Sun HQ; Vitiello MV; Tang XD; Zhou XY; Bao YP; Shi J; Lu L
    Sleep Med Rev; 2023 Apr; 68():101746. PubMed ID: 36701954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapies for sleep disturbances in dementia.
    McCleery J; Sharpley AL
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD009178. PubMed ID: 33189083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual orexin receptor antagonists for the treatment of insomnia: systematic review and network meta-analysis.
    Rocha RB; Bomtempo FF; Nager GB; Cenci GI; Telles JPM
    Arq Neuropsiquiatr; 2023 May; 81(5):475-483. PubMed ID: 37257468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity.
    De Boer P; Drevets WC; Rofael H; van der Ark P; Kent JM; Kezic I; Parapatics S; Dorffner G; van Gerven J; Beneš H; Keicher C; Jahn H; Seiden DJ; Luthringer R
    J Psychopharmacol; 2018 Jun; 32(6):668-677. PubMed ID: 29848147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective Orexin Receptor Antagonists as Novel Augmentation Treatments for Major Depressive Disorder: Evidence for Safety and Efficacy From a Phase 2B Study of Seltorexant.
    Jha MK
    Int J Neuropsychopharmacol; 2022 Jan; 25(1):85-88. PubMed ID: 34791262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.